Benjamin Kelmendi
Clinical Researcher
Data updated
Research Footprint
Benjamin Kelmendi appears in 13 tracked papers (2017–2026), most studied alongside MDMA, Psilocybin and Ketamine, across PTSD, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic (143 citations).
Frequent co-authors: John Krystal, Gabrielle Agin-Liebes and Joseph Barsuglia.
Publication Landscape
How the 13 papers Blossom tracks for Benjamin Kelmendi line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Benjamin Kelmendi's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Benjamin Kelmendi publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Benjamin Kelmendi publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Benjamin Kelmendi is a clinical researcher affiliated with contemporary academic programmes in psychedelic science, including contributions linked to the Yale Program for Psychedelic Science. His published and in‑progress work spans early‑phase human pharmacology, translational neurobiology and qualitative/attitudinal research relevant to the clinical deployment of psychedelic and entactogenic compounds.
Key contributions include authorship on preclinical and human‑focused manuscripts investigating methylone as a rapid‑acting entactogen and putative neuroplastogen with anxiolytic and antidepressant‑like effects, comparative pharmacology of methylone versus MDMA, and a case report with SPECT imaging and a theoretical rationale for sequential ibogaine and 5‑MeO‑DMT administration in alcohol use disorder. Kelmendi has also co‑authored work on mechanisms of therapeutic change following psychedelic treatment in obsessive‑compulsive disorder and on palliative care provider attitudes toward existential distress and psychedelic‑assisted therapies. His output reflects interdisciplinary engagement across neuropharmacology, substance use disorders and the evolving clinical frameworks for psychedelic interventions.
Key Impact
Kelmendi is an active contributor to contemporary clinical and preclinical investigations of novel entactogens and psychedelic-assisted approaches, with work spanning pharmacology, addiction treatment strategies and clinician attitudes toward psychedelic therapies.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Benjamin Kelmendi's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Benjamin Kelmendi is associated with.
Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →Transcend Therapeutics
Private BiotechTranscend Therapeutics is a private, New York-based clinical-stage company developing TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD and other neuropsychiatric conditions. Founded in 2021 by Blake Mandell (CEO), Kevin Ryan (AlleyCorp), and Dr. Benjamin Kelmendi (Yale), the company raised $41.5M from investors including the US Department of Defense. TSND-201 is non-hallucinogenic (no 5-HT2A activity) and requires no structured psychotherapy. Its Phase 2 IMPACT-1 trial met the primary endpoint (March 2025, published JAMA Psychiatry Feb 2026) and the FDA granted Breakthrough Therapy Designation in July 2025. Phase 3 programme is planned for 2026.
View stakeholder →